Sign in
CompletedNo phase

Trial Readiness and Endpoint Assessment in Congenital Myotonic Dystrophy

Key facts

Who runs it
Virginia Commonwealth University
Where
Richmond, United StatesSee the siteAlso in 2 other countries, 2 sites
Trial code
Status
Completed
People taking part
100 people enrolled
Started
14 Dec 2016
Ended
27 Jan 2025
Type of study
Observational, 2 groups
Treatments tested
  • Natural history
Record updated
11 March 2025

Who can take part

Age
0 years to 15 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Age 0-15 yrs
  • Diagnosis of CDM, based on symptoms and genetic testing of expanded trinucleotide repeats
  • Age 0-15 yrs
  • Healthy children on no medication

Who cannot take part

  • Any other non-DM1 illness that would interfere with the ability or results of the study in the opinion of site investigator
  • Any illness or situation that, in the opinion of the site investigator, has the possibility to interfere with study procedures
  • Significant trauma within one month
  • Internal metal or devices; Control Group
  • DM type 1 and 2

Other criteria

  • CDM Group

Where in United States

Also in 2 other countries, 2 sites

  • Virginia Commonwealth UniversityRichmond, United States

About the trial

What the trial wants to find out

Congenital Myotonic Dystrophy (CDM) is a multi-systemic, dominantly inherited disorder caused by a trinucleotide repeat expansion (CTGn) in the DMPK gene. CDM occurs when the CTGn increases between the adult myotonic dystrophy type-1 (DM1) parent and the child. Children with CDM present at birth with respiratory insufficiency, talipes equinovarus, feeding difficulties and hypotonia. There is a 30% mortality rate in the first year of life. As children grow, they are at risk for intellectual impairment, autistic features, gastrointestinal symptoms, and motor delay.

Read full original descriptionShow less

The investigators will enroll children with CDM between ages 0-15 with visits at baseline and one year to evaluate appropriate physical functional outcomes, cognitive function and quality of life over time. Functional outcome measures will be correlated with potential biomarkers in the children. Completion of these specific aims will extend the understanding of disease progression in CDM and will provide the requisite information for successful therapeutic trials in children with DM.

The 2 groups in the trial

  • CDM

    Children with Congenital Myotonic Dystrophy

    Treatment: Natural history

  • Control

    Healthy Children

    Treatment: Natural history

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Publications
Record updated
11 March 2025